Investment analysts at StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a research note issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
DURECT Stock Performance
Shares of NASDAQ:DRRX opened at $0.80 on Wednesday. The business has a fifty day moving average of $0.80 and a 200-day moving average of $1.04. DURECT has a twelve month low of $0.70 and a twelve month high of $1.88. The firm has a market cap of $24.83 million, a PE ratio of -1.31 and a beta of 0.91.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Richmond Brothers Inc. boosted its position in DURECT by 12.2% in the 4th quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after buying an additional 138,920 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of DURECT by 266.0% during the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 28,486 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in DURECT by 4.8% in the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 14,658 shares during the last quarter. Institutional investors own 28.03% of the company’s stock.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Featured Stories
- Five stocks we like better than DURECT
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- The How And Why of Investing in Oil Stocks
- 3 Must-Own Stocks to Build Wealth This Decade
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.